Sign In
Buy IOVA
$3.79
-0.310 (-7.56%)
At Close: Jun 03, 2026
Why Shares of Iovance Biotherapeutics Jumped Monday
03:56pm, Monday, 27'th Mar 2023
Iovance is looking for approval for a metastatic melanoma therapy. Company CEO Frederick Vogt said it would be the first individualized, one-time cell therapy for a solid tumor.
Iovance (IOVA) Completes Rolling BLA Filing for Melanoma Drug
12:59pm, Monday, 27'th Mar 2023
Following the completion of Iovance's (IOVA) regulatory filing for its lead candidate in melanoma indication, the FDA has 60 days to determine the acceptability of the BLA for review.
Iovance Biotherapeutics completes license application submission for advanced melanoma therapy; shares rally
07:55pm, Friday, 24'th Mar 2023
Biotech cancer-treatment developer Iovance Biotherapeutics Inc. IOVA, -3.83% on Friday said it had completed its rolling biologics license application submission to the U.S. Food and Drug Administrati
Iovance (IOVA) Q4 Earnings In Line With Estimates, Revenues Nil
12:47pm, Wednesday, 01'st Mar 2023
Iovance (IOVA) reports Q4 earnings in line with our estimates. Management is on track to complete the rolling BLA submission for lifileucel in melanoma before first-quarter 2023 ends.
Iovance Biotherapeutics to Present at Upcoming Conferences
08:03am, Wednesday, 01'st Mar 2023
SAN CARLOS, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today anno
Iovance Biotherapeutics, Inc. (IOVA) Q4 2022 Earnings Call Transcript
12:37am, Wednesday, 01'st Mar 2023
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA ) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Sara Pellegrino - Senior Vice President, Investor Relations and Corporat
SAN CARLOS, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report
Iovance: Capturing A Lucrative Market
06:33pm, Wednesday, 01'st Feb 2023
Iovance Biotherapeutics, Inc. is poised to complete its rolling Biologic License Application for advanced melanoma this quarter. The recent Proleukin acquisition ensures a strong supply of IL2 for its
Iovance (IOVA) to Buy Clinigen's Cancer Drug, Stock Up 11.6%
01:33pm, Tuesday, 24'th Jan 2023
Iovance (IOVA) to acquire worldwide rights to an IL-2 product already approved by FDA for two cancer indications. The deal is expected to close by first-quarter 2023.
Why Iovance Biotherapeutics Stock Soared 12% Higher Today
06:37pm, Monday, 23'rd Jan 2023
A business, clinical, and regulatory update lifted the spirits of investors.
3 Graham's Lost Formula Picks to Consider for the New Year
12:41pm, Thursday, 05'th Jan 2023
After ending 2022 on a low note, U.S. market indexes continued to sink on Thursday morning after jobs data showed the labor market is still hot despite the Federal Reserve's attempts to curb inflation
Iovance: Robust Fundamental Improvements
12:21pm, Thursday, 05'th Jan 2023
In the latest conference call, Iovance Biotherapeutics, Inc. management seemed quite confident in their ability to complete the rolling of BLA for lifileucel by this quarter. I believe that previous m
Why Is Iovance Biotherapeutics (IOVA) Stock Soaring 20% Today?
02:41pm, Monday, 05'th Dec 2022
Despite a rough day in the market over fears that the Federal Reserve may raise interest rates and thus induce a recession, biopharmaceutical startup Iovance Biotherapeutics (NASDAQ: IOVA ) stock shot
Iovance Biotherapeutics to Present at Upcoming Conferences
07:00am, Wednesday, 30'th Nov 2022
SAN CARLOS, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today annou
Iovance: Rolling BLA Development Signals More Upside
11:44am, Tuesday, 29'th Nov 2022
In the latest filing, Iovance Biotherapeutics, Inc. stated that they received guidance from the FDA for lifileucel's rolling BLA. The company is expected to complete the said filing by the first quart
